摘要
目的检测不同类型骨肿瘤患者血浆热休克蛋白90α(Hsp90α)水平,探讨Hsp90α在骨肿瘤临床诊断中的应用。方法选取2017年12月至2019年2月本院收治的经病理确诊为骨肿瘤患者157例(骨肿瘤组),按照肿瘤病理类别分为恶性骨肿瘤组(n=69)、良性骨肿瘤组(n=58)、交界性骨肿瘤组(n=30),并以32名体检健康者作为正常对照组。其中恶性骨肿瘤组又分为原发性恶性肿瘤组(n=45)和骨转移性肿瘤组(n=24)。用酶联免疫吸附试验(ELISA)测定血浆hsp90α水平,比较Hsp90α在各组的水平,用ROC曲线分析确定血浆中Hsp90α表达的阈值和良性、恶性和结缔骨肿瘤的标准。结果骨肿瘤组Hsp90α水平为(88.93±42.3)ng/mL,明显高于正常对照组的(30.5±13.8)ng/mL,差异有统计学意义(t=-14.037,P<0.05)。恶性骨肿瘤组、交界性骨肿瘤组、良性骨肿瘤组与正常对照组血浆Hsp90α水平分别为(122.6±36.1)、(57.7±22.6)、(71.8±24.5)、(30.4±13.8)ng/mL。其中,恶性骨肿瘤组血浆Hsp90α水平明显高于交界性骨肿瘤组和良性肿瘤骨组,差异有统计学意义(P<0.001);良性骨肿瘤组与交界性骨肿瘤组血浆Hsp90α水平比较差异无统计学意义(P=0.064)。血浆Hsp90α水平诊断恶性骨肿瘤、交界性骨肿瘤、良性肿瘤组的阈值分别为68.77、37.52、42.81 ng/mL;血浆Hsp90α诊断恶性骨肿瘤的灵敏度为97.3%,特异度为99.8%,交界性骨肿瘤的灵敏度为78.4%,特异度为99.8%,良性骨肿瘤的灵敏度为89.6%,特异度为87.7%。原发性恶性骨肿瘤组血浆Hsp90α水平为(120.3±37.5)ng/mL,与转移性骨肿瘤组(126.9±33.5)ng/mL比较差异无统计学意义(t=-0.716,P=0.476)。结论骨肿瘤患者血浆中HSP-90α水平高表达,对骨肿瘤诊断、判断良恶性具有一定的价值。
Objective To detect the plasma heat shock protein 90α(Hsp90α)levels in patients with different types of bone tumors,and to investigate the clinical application of Hsp90αin the diagnosis of bone tumors.Methods 157 patients with pathologically confirmed bone tumor admitted to our hospital from December 2017 to February 2019(bone tumor group)were selected and divided into malignant bone tumor group(n=69),benign bone tumor group(n=58)and borderline bone tumor group(n=30)according to tumor types.32 healthy people were used as the normal control group.The malignant bone tumor group was further divided into primary malignant tumor group(n=45)and bone metastatic tumor group(n=24).Plasma Hsp90αlevels were measured by enzyme-linked immunosorbent assay(ELISA),and Hsp90αlevels were compared in each group.ROC curve analysis was used to determine the plasma Hsp90αexpression threshold and the criteria for benign,malignant,and connective bone tumors.Results The Hsp90αlevel in bone tumor group was(88.93±42.3)ng/mL,significantly higher than that in normal control group(30.5±13.8)ng/mL(t=-14.037,P<0.05).Plasma Hsp90αwas(122.6±36.1)ng/mL in the malignant bone tumor group,(57.7±22.6),(71.8±24.5)ng/mL in the borderline bone tumor group,and(30.4±13.8)ng/mL in the benign bone tumor group and the control group,respectively.The plasma Hsp90αlevel in the malignant bone tumor group was significantly higher than that in the borderline bone tumor group and the benign bone tumor group(P<0.001).There was no significant difference in plasma Hsp90αbetween benign and borderline bone tumors(P=0.064).The threshold values for the diagnosis of malignant bone tumor,borderline bone tumor and benign tumor were 68.77,37.52 and 42.81 ng/mL,respectively.The sensitivity and specificity of plasma Hsp90αin the diagnosis of malignant bone tumors were 97.3%,99.8%,78.4%,99.8%,89.6%and 87.7%respectively for borderline bone tumors and begin bone tumors.The plasma Hsp90αlevel in the primary malignant bone tumor group was(120.3±37.5)ng/mL,but there
作者
王园
胡勇
徐生林
阙玉康
许唐兵
Wang Yuan;Hu Yong;Xu Shenglin;Que Yukang;Xu Tangbing(Department of Bone Disease and Bone Tumor Surgery,The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,230032,China;Department of Orthopedics,the Fourth Affiliated Hospital of Anhui Medical University,Hefei,Anhui,230032,China)
出处
《当代医学》
2020年第27期100-102,共3页
Contemporary Medicine
基金
安徽省自然科学基金项目(1708085MH215)
安徽医科大学校基金(2015xkj088)。
